ERBB2 and breast cancer: The 21-gene recurrence risk score (RS) is computed on the basis of the expression levels of these genes and has been widely used to predict the risk of distant recurrence and the potential benefit of adjuvant chemotherapy in women with ER-positive, HER2-negative early-stage breast cancer (3–5).